ArticleCureus2024
Long-Term Dysphagia Severity in Patients With Idiopathic Inflammatory Myopathy: A Single-Center Retrospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Update on Dermatomyositis and Related Inflammatory Myopathies: Cutaneous Clues, Skeletal Muscle Involvement, and Advances in Pathogenesis and Treatment.Muscles (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To investigate long-term dysphagia severity and survival outcomes in patients with idiopathic inflammatory myopathy (IIM). Methods We retrospectively included consecutive Japanese patients with IIM between April 2000 and March 2022. The primary endpoint was the complete oral intake rate according to the Food Intake LEVEL Scale (FILS) within one year after the onset of dysphagia in patients with IIM.The secondary outcome was the overall mortality rate in IIM patients with dysphagia. Results Of the 108 patients with IIM, 18 (16.7%) developed dysphagia during the observation period. The baseline median dysphagia severity in IIM patients with dysphagia using the FILS was 7.0 and improved to 10.0 at the final observation. Almost all IIM patients recovered from dysphagia severity, and the complete oral intake rate within one year in IIM patients with dysphagia was 72.2%. The overall mortality rate of patients with IIM patients with dysphagia was 44.4%, which is significantly lower than that of those without dysphagia (P < 0.05). Cox regression analysis demonstrated that malignancy-associated myositis was a poor prognostic factor in patients with IIM and survival outcomes in IIM patients with dysphagia were poor compared with those in patients without dysphagia when with malignancies. Conclusions The dysphagia severity in patients with IIM improved; however, their survival rate was lower than that of those without dysphagia when malignancy occurred.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.